Bio-Techne Corporation

BIT:1TECH Stock Report

Market Cap: €8.3b

Bio-Techne Valuation

Is 1TECH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1TECH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

€61.99
Fair Value
12.9% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: 1TECH (€54) is trading below our estimate of fair value (€61.99)

Significantly Below Fair Value: 1TECH is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1TECH?

Key metric: As 1TECH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1TECH. This is calculated by dividing 1TECH's market cap by their current earnings.
What is 1TECH's PE Ratio?
PE Ratio123.3x
EarningsUS$77.95m
Market CapUS$9.61b

Price to Earnings Ratio vs Peers

How does 1TECH's PE Ratio compare to its peers?

The above table shows the PE ratio for 1TECH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.5x
FF Fine Foods & Pharmaceuticals N.T.M
18.2x21.76%€228.4m
REC Recordati Industria Chimica e Farmaceutica
24.7x14.91%€10.0b
QGEN Qiagen
25.1x10.52%US$10.2b
2268 WuXi XDC Cayman
57.9x26.35%HK$84.6b
1TECH Bio-Techne
123.3x23.60%€9.6b

Price-To-Earnings vs Peers: 1TECH is expensive based on its Price-To-Earnings Ratio (123.3x) compared to the peer average (31.5x).

Price to Earnings Ratio vs Industry

How does 1TECH's PE Ratio compare vs other companies in the European Life Sciences Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
1TECH 123.3xIndustry Avg. 34.2xNo. of Companies3PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1TECH is expensive based on its Price-To-Earnings Ratio (123.3x) compared to the Global Life Sciences industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is 1TECH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1TECH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio123.3x
Fair PE Ratio36.3x

Price-To-Earnings vs Fair Ratio: 1TECH is expensive based on its Price-To-Earnings Ratio (123.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1TECH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€54.00
€59.70
+10.56%
6.83%€64.74€51.79n/a12
Nov ’26€54.50
€58.49
+7.33%
8.23%€64.67€50.88n/a12
Oct ’26€49.40
€56.11
+13.59%
10.32%€64.09€45.29n/a12
Sep ’26€46.40
€55.90
+20.47%
10.15%€64.19€45.36n/a13
Aug ’26€46.60
€58.21
+24.91%
11.95%€70.02€48.14n/a14
Jul ’26€44.60
€57.12
+28.07%
16.07%€76.41€43.30n/a13
Jun ’26€43.00
€61.00
+41.86%
17.34%€79.27€44.92n/a13
May ’26€44.00
€70.07
+59.25%
15.36%€83.52€44.84n/a12
Apr ’26n/a
€77.74
0%
10.94%€88.06€63.03n/a13
Mar ’26n/a
€81.94
0%
9.15%€91.13€65.23n/a13
Feb ’26n/a
€81.44
0%
6.70%€90.57€71.51n/a13
Jan ’26n/a
€81.82
0%
6.72%€91.16€71.97n/a13
Dec ’25n/a
€78.38
0%
6.72%€87.34€68.96€55.5013
Nov ’25n/a
€78.38
0%
6.72%€87.34€68.96€54.5013
Oct ’25n/a
€75.07
0%
8.27%€85.83€58.73€49.4013
Sep ’25n/a
€75.22
0%
9.17%€86.56€59.23€46.4013
Aug ’25n/a
€76.76
0%
9.20%€87.19€59.66€46.6013
Jul ’25n/a
€77.79
0%
9.66%€87.96€60.18€44.6013
Jun ’25n/a
€77.79
0%
9.66%€87.96€60.18€43.0013
May ’25n/a
€76.12
0%
10.33%€88.85€60.79€44.0011
Apr ’25n/a
€74.47
0%
8.61%€88.07€60.26n/a13
Mar ’25n/a
€74.47
0%
8.61%€88.07€60.26n/a13
Feb ’25n/a
€74.16
0%
9.19%€87.40€59.80n/a12
Jan ’25n/a
€71.93
0%
11.64%€86.05€58.88n/a13
Dec ’24n/a
€71.23
0%
12.16%€87.10€59.59n/a12
€60.55
Fair Value
10.8% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/07 05:23
End of Day Share Price 2025/12/05 00:00
Earnings2025/09/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Techne Corporation is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Catherine Ramsey SchulteBaird
Robert WassermanBenchmark Company